Geode Capital Management LLC Cuts Position in Inogen, Inc. (NASDAQ:INGN)

Geode Capital Management LLC trimmed its holdings in shares of Inogen, Inc. (NASDAQ:INGN) by 0.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 552,596 shares of the medical technology company’s stock after selling 1,595 shares during the period. Geode Capital Management LLC owned about 2.32% of Inogen worth $5,069,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of INGN. AlphaQuest LLC acquired a new stake in Inogen in the fourth quarter valued at $43,000. Meeder Asset Management Inc. bought a new stake in shares of Inogen in the 4th quarter worth about $56,000. Ieq Capital LLC acquired a new stake in shares of Inogen in the 4th quarter valued at about $94,000. Intech Investment Management LLC bought a new position in shares of Inogen during the fourth quarter worth about $94,000. Finally, Summit Global Investments acquired a new position in Inogen in the fourth quarter worth about $107,000. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Inogen Price Performance

NASDAQ INGN opened at $7.28 on Friday. Inogen, Inc. has a 12 month low of $6.40 and a 12 month high of $13.33. The company has a market capitalization of $195.74 million, a P/E ratio of -3.24 and a beta of 1.48. The company’s 50 day simple moving average is $7.59 and its 200 day simple moving average is $9.06.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Wednesday, April 9th. StockNews.com downgraded Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 26th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.